Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $6.03 million. The enterprise value is $1.94 million.

Market Cap	6.03M
Enterprise Value	1.94M

Important Dates

The next estimated earnings date is Tuesday, December 31, 2024, after market close.

Earnings Date	Dec 31, 2024
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 5.43 million shares outstanding. The number of shares has increased by 118.23% in one year.

Current Share Class	5.43M
Shares Outstanding	5.43M
Shares Change (YoY)	+118.23%
Shares Change (QoQ)	+354.05%
Owned by Insiders (%)	0.49%
Owned by Institutions (%)	2.40%
Float	5.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.55
P/TBV Ratio	1.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.80

Current Ratio	3.80
Quick Ratio	3.26
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-299.69

Financial Efficiency

Return on equity (ROE) is -1,092.96% and return on invested capital (ROIC) is -680.83%.

Return on Equity (ROE)	-1,092.96%
Return on Assets (ROA)	-121.64%
Return on Capital (ROIC)	-680.83%
Revenue Per Employee	n/a
Profits Per Employee	-$843,367
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.44% in the last 52 weeks. The beta is -0.06, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	-88.44%
50-Day Moving Average	1.43
200-Day Moving Average	4.14
Relative Strength Index (RSI)	34.54
Average Volume (20 Days)	174,662

Short Selling Information

The latest short interest is 132,917, so 2.45% of the outstanding shares have been sold short.

Short Interest	132,917
Short Previous Month	144,256
Short % of Shares Out	2.45%
Short % of Float	2.50%
Short Ratio (days to cover)	1.03

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.83M
Pretax Income	-9.95M
Net Income	-5.90M
EBITDA	-5.78M
EBIT	-5.83M
Earnings Per Share (EPS)	-$4.14

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	4.09M
Total Debt	n/a
Net Cash	4.09M
Net Cash Per Share	$0.75
Equity (Book Value)	3.75M
Book Value Per Share	0.72
Working Capital	3.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.91 million and capital expenditures -$90,000, giving a free cash flow of -$8.00 million.

Operating Cash Flow	-7.91M
Capital Expenditures	-90,000
Free Cash Flow	-8.00M
FCF Per Share	-$1.47

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-118.23%
Shareholder Yield	-118.23%
Earnings Yield	-97.90%
FCF Yield	-132.73%

Analyst Forecast

The average price target for Alzamend Neuro is $32.00, which is 2,782.88% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.00
Price Target Difference	2,782.88%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 16, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jul 16, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1